Home Biologics

Keyword: Biologics

80 results found

Severe asthma is a complex condition that impacts between 150,000 and 250,000 Canadians, according to Vanessa Foran, president and chief executive officer of Asthma Canada, during a webinar hosted last month by Benefits Canada and supported by AstraZeneca. It’s an acute condition where people have difficulty achieving control of their disease despite proper use of […]

While medications used for treating inflammatory disease accounted for just 0.7 per cent of claims across Telus Health’s Canadian block of business in 2021, they represent the largest percentage of eligible drug costs at 12.6 per cent, due to the prevalence of high-cost treatments in this drug class. By comparison, diabetes medications accounted for 12 […]

Copyright_Wavebreak Media Ltd_123RF

Changes to Quebec’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans, says one expert. On April 13, 2022, the Régie de l’assurance maladie du Québec will delist certain biologic drugs from its formulary, requiring patients covered by the plan to switch to a biosimilar […]

It took an “intense, painful and scary” flare and emergency surgery at age 38 for Marie-Josée Lafleur (pictured right) to finally be diagnosed with inflammatory bowel disease, after being misdiagnosed for 15 years. IBD, which is typically diagnosed between ages 16 and 30, is caused by the body’s immune system attacking the gastrointestinal tract, creating […]

Copyright_Aleksandr Kalugin_123RF

In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]

While one side highlights how plan sponsors can contribute to biosimilar sustainability, the other touts the benefits to patients and the health-care system. Durhane Wong-Rieger, president and chief executive officer, Institute for Optimizing Health Outcomes The Institute for Optimizing Health Outcomes recently published a scorecard rating the biosimilar policy frameworks of European countries across seven […]

Copyright_ spirer_123RF

The Canadian Life and Health Insurance Association is calling on the federal government to permit standalone variable payment life annuities to pool participants from all registered retirement plans. In its 2022 federal budget submission, the CLHIA said VPLAs, as enacted, will only be available to members of very large defined contribution pension plans, excluding Canadians […]

  • By: Staff
  • August 9, 2021 August 9, 2021
  • 15:00
Copyright_Aleksandr Kalugin_123RF

Canadians’ health priorities are shifting as the coronavirus pandemic drags on, as claims for medications to treat mental-health conditions continued to rise in 2020, along with claims for specialty drugs designed to treat rarer, yet increasingly chronic diseases, according to Telus Health’s annual drug trends report. There were noticeable shifts in the utilization of mental-health […]

The growing use of specialty medications among plan members continued to drive the increase in plan sponsors’ drug plan costs last year, well eclipsing the increase in traditional drug spending, according to Telus Health. Canadian plan sponsors’ drug spending on insured plan members between the ages of 25 and 64 increased 3.6 per cent in […]

Copyright_Mikhail Tsikhanovich_123RF

The New Brunswick government is expanding the use of biosimilars for certain chronic conditions in its public drug plans. Approximately 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from a biologic to the biosimilar […]

  • By: Staff
  • April 23, 2021 April 26, 2021
  • 15:00